Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Vatalanib and everolimus may stop the growth of tumor cells by blocking blood flow
to the tumor and by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of vatalanib and
everolimus and to see how well they work in treating patients with advanced solid tumors.